For TGFB3 and SATB1 this difference is small, with the genes repositioned in ∼33.3% (5/15 and 6/16 respectively; false negative rate ∼66.7%) of non-metastatic cancers and 16.7% (1/6) of metastatic cancers (Table 3 and 4). Here, SATB1 is linked to metastatic malignant neoplasm.